What is MBRX's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.01B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for MBRX?

P/E (TTM) is n/a and 52-week range is $0.16 to $15.75 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s MBRX figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for MBRX?

The company profile lists net income (TTM) near $-103M, EPS (TTM) near $-14.53 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Moleculin Biotech Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Houston, Texas, US, 7.1M shares outstanding, ISIN US60855D4088 when available from company profile and filing metadata.

Moleculin Biotech Inc

$MBRX

Health Care · Biotechnology

IR Run Scenarios

$0.44

+4.25%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company. The company is headquartered in Houston, Texas and currently employs 17 full-time employees. The company went IPO on 2016-06-02. The firm is conducting a pivotal Phase III trial evaluating Annamycin, a non-cardiotoxic anthracycline, in combination with Cytarabine for the treatment of subjects with relapsed/refractory acute myeloid leukemia (AML). The company has three core technologies and six drug candidates, three of which have shown human activity in clinical trials. Its core technologies consist of Annamycin, WP1066 Portfolio, and WP1122 Portfolio. Annamycin is designed to avoid multidrug resistance mechanisms and cardiotoxicity. Its WP1066, is an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other transcription factors, and its portfolio includes WP1193, and WP1220. Its WP1122 contains compounds including WP1096, and WP1097, which is designed to exploit the potential uses of inhibitors of glycolysis such as 2-deoxy-D-glucose (2-DG).

Employees

Website

moleculin.com/

IPO

2016-06-02

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)